{"id":"W2045324973","doi":"10.1016/s0140-6736(07)60028-2","title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1511,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Institute of Cancer Research","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Clinical trial; Chemotherapy; Adjuvant; Cancer; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00456464,0.003051752,0.007672349,0.0006691964,0.0008425119,0.002174023,0.001865036,0.005768951,0.009408829],"category_scores_gemma":[0.006243457,0.001608285,0.005529016,0.0009433581,0.002274588,0.00255973,0.001109112,0.006683202,0.001446211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001866025,"about_ca_system_score_gemma":0.001675513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003384917,"about_ca_topic_score_gemma":0.00354606,"domain_scores_codex":[0.9968643,0.001672205,0.0002173343,0.0005664721,0.0001742994,0.0005053386],"domain_scores_gemma":[0.9965045,0.001432048,0.0007496455,0.0004191484,0.0002081166,0.0006864309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9963177,0.0006488695,0.0002109303,0.0002708132,0.0008184753,0.00001969163,0.00001759883,0.00008618982,0.0001920436,0.00003269824,0.0001455711,0.001239384],"study_design_scores_gemma":[0.9807087,0.01593056,0.001122155,0.00005763672,0.0014696,0.00001630245,0.00001811704,0.0001930418,0.0000847381,0.00012811,0.0002548701,0.00001612175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9653976,0.01902366,0.001247847,0.001980045,0.004116011,0.003852542,0.001503649,0.0001810966,0.002697595],"genre_scores_gemma":[0.9830387,0.004301418,0.0009142993,0.001494603,0.001298882,0.003722663,0.001128432,0.00003148272,0.00406957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009408829,"threshold_uncertainty_score":0.03147566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02317066928127298,"score_gpt":0.3436008290136301,"score_spread":0.3204301597323572,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}